N-Succinylaspartic-Acid-Conjugated Riluzole Is a Safe and Potent Colon-Targeted Prodrug of Riluzole against DNBS-Induced Rat Colitis

In our previous study, riluzole azo-linked to salicylic acid (RAS) was prepared as a colon-targeted prodrug of riluzole (RLZ) to facilitate the repositioning of RLZ as an anticolitic drug. RAS is more effective against rat colitis than RLZ and sulfasalazine, currently used as an anti-inflammatory bo...

Full description

Saved in:
Bibliographic Details
Main Authors: Jaejeong Kim (Author), Changyu Kang (Author), Jin-Wook Yoo (Author), In-Soo Yoon (Author), Yunjin Jung (Author)
Format: Book
Published: MDPI AG, 2023-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9ea6f3d0f61a46de8c9dd9642f64ae1b
042 |a dc 
100 1 0 |a Jaejeong Kim  |e author 
700 1 0 |a Changyu Kang  |e author 
700 1 0 |a Jin-Wook Yoo  |e author 
700 1 0 |a In-Soo Yoon  |e author 
700 1 0 |a Yunjin Jung  |e author 
245 0 0 |a N-Succinylaspartic-Acid-Conjugated Riluzole Is a Safe and Potent Colon-Targeted Prodrug of Riluzole against DNBS-Induced Rat Colitis 
260 |b MDPI AG,   |c 2023-11-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15112638 
500 |a 1999-4923 
520 |a In our previous study, riluzole azo-linked to salicylic acid (RAS) was prepared as a colon-targeted prodrug of riluzole (RLZ) to facilitate the repositioning of RLZ as an anticolitic drug. RAS is more effective against rat colitis than RLZ and sulfasalazine, currently used as an anti-inflammatory bowel disease drug. The aim of this study is to further improve colon specificity, anticolitic potency, and safety of RAS. N-succinylaspart-1-ylRLZ (SAR) and N-succinylglutam-1-ylRLZ (SGR) were synthesized and evaluated as a "me-better" colon-targeted prodrug of RLZ against rat colitis. SAR but not SGR was converted to RLZ in the cecal contents, whereas both conjugates remained intact in the small intestine. When comparing the colon specificity of SAR with that of RAS, the distribution coefficient and cell permeability of SAR were lower than those of RAS. In parallel, oral SAR delivered a greater amount of RLZ to the cecum of rats than oral RAS. In a DNBS-induced rat model of colitis, oral SAR mitigated colonic damage and inflammation and was more potent than oral RAS. Moreover, upon oral administration, SAR had a greater ability to limit the systemic absorption of RLZ than RAS, indicating a reduced risk of systemic side effects of SAR. Taken together, SAR may be a "me-better" colon-targeted prodrug of RLZ to improve the safety and anticolitic potency of RAS, an azo-type colon-targeted prodrug of RLZ. 
546 |a EN 
690 |a riluzole 
690 |a colon-targeted drug delivery 
690 |a colitis 
690 |a prodrug 
690 |a N-succinylated acidic amino acids 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 11, p 2638 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/11/2638 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/9ea6f3d0f61a46de8c9dd9642f64ae1b  |z Connect to this object online.